- Home
- AGIO vs TASK Comparison
AGIO vs TASK Comparison
Compare AGIO & TASK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AGIO
- TASK
- Stock Information
- Founded
- AGIO 2007
- TASK 2008
- Country
- AGIO United States
- TASK United States
- Employees
- AGIO N/A
- TASK N/A
- Industry
- AGIO Biotechnology: Pharmaceutical Preparations
- TASK Retail: Computer Software & Peripheral Equipment
- Sector
- AGIO Health Care
- TASK Technology
- Exchange
- AGIO Nasdaq
- TASK Nasdaq
- Market Cap
- AGIO 1.4B
- TASK 1.5B
- IPO Year
- AGIO 2013
- TASK 2021
- Fundamental
- Price
- AGIO $32.09
- TASK $16.60
- Analyst Decision
- AGIO Buy
- TASK Buy
- Analyst Count
- AGIO 8
- TASK 7
- Target Price
- AGIO $56.00
- TASK $16.86
- AVG Volume (30 Days)
- AGIO 550.4K
- TASK 897.0K
- Earning Date
- AGIO 05-01-2025
- TASK 05-09-2025
- Dividend Yield
- AGIO N/A
- TASK N/A
- EPS Growth
- AGIO N/A
- TASK 15.14
- EPS
- AGIO 11.45
- TASK 0.60
- Revenue
- AGIO $37,035,000.00
- TASK $1,045,307,000.00
- Revenue This Year
- AGIO $27.43
- TASK $14.78
- Revenue Next Year
- AGIO $189.81
- TASK $9.28
- P/E Ratio
- AGIO $2.80
- TASK $27.62
- Revenue Growth
- AGIO 25.96
- TASK 14.05
- 52 Week Low
- AGIO $23.42
- TASK $10.57
- 52 Week High
- AGIO $62.58
- TASK $19.60
- Technical
- Relative Strength Index (RSI)
- AGIO 65.51
- TASK 65.76
- Support Level
- AGIO $29.05
- TASK $16.47
- Resistance Level
- AGIO $30.45
- TASK $16.89
- Average True Range (ATR)
- AGIO 1.13
- TASK 0.22
- MACD
- AGIO 0.33
- TASK -0.06
- Stochastic Oscillator
- AGIO 91.98
- TASK 26.53
About AGIO Agios Pharmaceuticals Inc.
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236, and others.
About TASK TaskUs Inc.
TaskUs Inc is a provider of outsourced digital services and next-generation customer experience to the world's most innovative companies, helping its clients represent, protect and grow their brands. It serves clients in the fastest-growing sectors, including social media, e-commerce, gaming, streaming media, food delivery and ridesharing, HiTech, FinTech and HealthTech.